COVID 19 Vaccine Programs Update

Featured Journal Content


COVID 19 Vaccine Programs Update

Johnson & Johnson Announces European Commission Approval of Agreement to Supply 200 Million Doses of Janssen’s COVID-19 Vaccine Candidate
Oct 08, 2020
Agreement provides option for European Union Member States to secure up to 200 million additional doses for a total of up to 400 million doses
NEW BRUNSWICK, N.J., Oct. 8, 2020 /PRNewswire/ Johnson & Johnson (NYSE: JNJ) (the Company) today announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Purchase Agreement in which the Janssen Pharmaceutical Companies will supply 200 million doses of its COVID-19 vaccine ..
candidate to EU Member States following approval or authorization from regulators. The EU Member States also have the option to secure up to 200 million additional doses…

DARPA Awards Moderna up to $56 Million to Enable Small-Scale, Rapid Mobile Manufacturing of Nucleic Acid Vaccines and Therapeutics
October 08, 2020
Award part of DARPA’s Nucleic Acids On-Demand World-Wide (NOW) initiative to develop a medical countermeasure manufacturing platform.
…Award involves development of a mobile manufacturing protype leveraging Moderna’s existing manufacturing technology that is capable of rapidly producing vaccines and therapeutics.

Moderna Announces Updates on Respiratory Syncytial Virus (RSV) Vaccine Program
October 08, 2020
Moderna regains rights to adult RSV vaccine program from Merck
Start of Phase 1 dosing for mRNA-1345, Moderna’s vaccine candidate against RSV 
Moderna has consolidated all rights to its prophylactic vaccines portfolio
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has regained all rights to the respiratory syncytial virus (RSV) vaccine (mRNA-1172) from Merck, known as MSD outside the United States and Canada, including rights to develop RSV vaccines for adult populations. mRNA-1172, which uses a Merck lipid nanoparticle for delivery, entered Phase 1 development in 2019. Under the terms of the agreement, Merck will complete the Phase 1 study and transition the program to Moderna. Moderna has now consolidated all global commercial rights to all development candidates in its core prophylactic vaccines modality…

Accenture Launches Vaccine Management Solution to Support COVID-19 Immunization Programs
October 07, 2020
Solution includes modular components to fit varying public health authorities’ needs and priorities
NEW YORK–(BUSINESS WIRE)–Accenture (NYSE: ACN) today announced a comprehensive vaccine management solution to help government and healthcare organizations rapidly and effectively plan and develop COVID-19 vaccination programs and related distribution and communication initiatives.
The solution expands on Accenture’s contact tracing capability to help public health jurisdictions meet newly released guidelines from the U.S. Centers for Disease Control and Prevention (CDC) in preparation for COVID-19 vaccine distribution. It brings together Accenture’s industry, analytics and consulting experience and includes components built on the Salesforce platform. Local, state and national governments as well as healthcare organizations worldwide are expected to similarly undertake planning, development, coordination, distribution and management of COVID-19 immunization programs…